# Zelasudil

**Cat. No.:** HY-148808

**CAS No.:** 2365193-22-0

**Molecular Formula:** $C_{22}H_{21}F_2N_7O$

**Molecular Weight:** 437.45

**Target:** ROCK

**Pathway:** Cell Cycle/DNA Damage; Cytoskeleton; Stem Cell/Wnt; TGF-beta/Smad

**Storage:**

| | | |
|---|---|---|
| Powder | -20°C | 3 years |
| | 4°C | 2 years |
| In solvent | -80°C | 6 months |
| | -20°C | 1 month |



## SOLVENT & SOLUBILITY

**In Vitro**

DMSO : 100 mg/mL (228.60 mM; Need ultrasonic)

**Preparing Stock Solutions**

| Solvent / Mass / Concentration | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 2.2860 mL | 11.4299 mL | 22.8598 mL |
| 5 mM | 0.4572 mL | 2.2860 mL | 4.5720 mL |
| 10 mM | 0.2286 mL | 1.1430 mL | 2.2860 mL |

Please refer to the solubility information to select the appropriate solvent.

**In Vivo**

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: 2.5 mg/mL (5.71 mM); Clear solution; Need ultrasonic
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: 2.5 mg/mL (5.71 mM); Clear solution; Need ultrasonic

## BIOLOGICAL ACTIVITY

**Description**

Zelasudil is a Rho-associated (ROCK) kinase inhibitor. Zelasudil has a ROCK2 binding affinity[1][2].

## REFERENCES

[1]. Lee E, et al. Selective ROCK2 inhibition for treatment of edema and associated conditions: World Intellectual Property Organization, WO2022169946. 2022-08-11.

[2]. WHO Drug Information-World Health Organization (WHO).

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA